Sherlock Biosciences, a Boston, MA-based biology diagnostics company, raised $80M in Series B funding.
The round was led by Novalis LifeSciences with participation from Illumina Ventures, Albany Capital and Catalio Capital Management. Paul Meister, Partner at Novalis LifeSciences, who will be joining the Sherlock Biosciences Board of Directors.
The company intends to use the funds to expand products and partnerships.
Led by CEO Bryan Dechairo, Sherlock Biosciences is a company engineering biology to bring next-generation diagnostics to the point-of-need. Powered by CRISPR and synthetic biology, Sherlock’s proprietary engineering biology tools form the foundation of its decentralized diagnostic platform for DNA and RNA detection. Through its engineering biology tools, CRISPR-based SHERLOCK™ and synthetic biology-based INSPECTR™, the company brings together the accuracy of PCR with the convenience of antigen tests for molecular diagnostics at the point-of-need. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, making it well suited for use in the home and in low resource settings, opening up a wide range of potential applications in areas including infectious disease, early detection of cancer, treatment monitoring, and precision medicine. In 2020 the company made history with the first FDA-authorized use of CRISPR technology.
FinSMEs
08/03/2022